RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Brigrajac, In the R+R presentation, Dr. Lippa said he wants to concentrate on getting CX-1739 into the clinic for both opiate induced RD (starting Q1-15) and Propofol induced RD (starting Q2-15). That's a tall order, and will require raising considerable funds.

While the ongoing SA Phase 2b with Dronabinol is fully paid for, Dronabinol isn't exactly a high profile program, being generic and all, so getting the Ampakines back into the clinic is a big priority.

It'll be nice having multiple programs again, something Cortex hasn't had in a long time. How Dr. Lippa will manage the funding side will be interesting. I'm following Cortex out of general interest, so mainly just want to see Ampakines back in the clinic.